Moderna’s COVID-19 vaccine candidate appears safe for human use, the company said today as it released results from the phase 1 trial of mRNA-1273. The dose-dependent trial sets the stage for a phase 2 trial, expected to start shortly and a larger phase 3 trial which will begin in July. The phase 1 trail showed an immune response in a small number healthy adult participants (8), who produced neutralizing antibodies to the virus that were similar to the antibodies seen in convalescent COVID-19 patient’s plasma. “With today’s positive interim phase 1 data and the positive data in the mouse challenge model, the Moderna team continues to focus on moving as fast as safely possible to start our pivotal phase 3 study in July and, if successful, file a BLA,” said Stephane Bancel, chief executive officer at Moderna. “We are investing to scale up manufacturing so we can maximize the number of doses we can produce to help protect as many people as we can from SARS-CoV-2.”

 

Credit: iStock, South_agency

Read more CIDRAP…